X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4929) 4929
Publication (406) 406
Book Review (19) 19
Book Chapter (7) 7
Conference Proceeding (5) 5
Magazine Article (5) 5
Data Set (2) 2
Dissertation (2) 2
Book / eBook (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (3181) 3181
male (2959) 2959
pyrrolidines - pharmacology (2505) 2505
humans (2013) 2013
rats (1952) 1952
index medicus (1585) 1585
female (1455) 1455
pharmacology & pharmacy (1167) 1167
pyrrolidines - administration & dosage (1083) 1083
pyrrolidines - therapeutic use (902) 902
mice (881) 881
dose-response relationship, drug (774) 774
neurosciences (724) 724
adult (707) 707
middle aged (681) 681
rats, sprague-dawley (634) 634
3,4-dichloro-n-methyl-n--cyclohexyl (489) 489
time factors (455) 455
aged (429) 429
administration, oral (400) 400
pyrrolidines - pharmacokinetics (398) 398
pyrrolidines - adverse effects (379) 379
adamantane - analogs & derivatives (375) 375
pyrrolidines - chemistry (369) 369
analgesics - pharmacology (359) 359
rats, wistar (354) 354
rats, inbred strains (311) 311
disease models, animal (303) 303
pyrrolidines (297) 297
receptors, opioid, kappa - agonists (294) 294
treatment outcome (280) 280
pyrrolidines - metabolism (274) 274
endocrinology & metabolism (271) 271
diabetes mellitus, type 2 - drug therapy (265) 265
rat (265) 265
double-blind method (264) 264
analysis (263) 263
biochemistry & molecular biology (254) 254
morphine - pharmacology (253) 253
morphine (232) 232
chemistry, medicinal (226) 226
brain - metabolism (216) 216
brain (213) 213
article (212) 212
expression (211) 211
pyrrolidine dithiocarbamate (200) 200
vildagliptin (198) 198
thiocarbamates - pharmacology (196) 196
psychiatry (193) 193
motor activity - drug effects (191) 191
dopamine (187) 187
blood pressure - drug effects (186) 186
research (186) 186
brain - drug effects (185) 185
in vitro techniques (184) 184
adamantane - therapeutic use (183) 183
adolescent (183) 183
kinetics (179) 179
pharmacokinetics (179) 179
type 2 diabetes (179) 179
structure-activity relationship (177) 177
behavior, animal - drug effects (175) 175
nitriles - therapeutic use (175) 175
naloxone - pharmacology (174) 174
inhibition (171) 171
oxidative stress (171) 171
receptors, opioid, kappa (171) 171
inflammation (169) 169
activation (168) 168
drug interactions (168) 168
rodents (167) 167
drug therapy, combination (164) 164
dogs (163) 163
drugs (163) 163
benzeneacetamides (160) 160
heart rate - drug effects (160) 160
in-vivo (157) 157
dopamine - metabolism (156) 156
kainic acid - pharmacology (156) 156
care and treatment (154) 154
mice, inbred c57bl (154) 154
injections, intravenous (153) 153
naltrexone - pharmacology (152) 152
diabetes (149) 149
hypoglycemic agents - therapeutic use (149) 149
pyrrolidines - toxicity (149) 149
enkephalins - pharmacology (148) 148
receptors (145) 145
drug therapy (144) 144
injections, intraventricular (144) 144
dipeptidyl-peptidase iv inhibitors - therapeutic use (143) 143
nitriles - pharmacology (143) 143
medicine, research & experimental (141) 141
pyrrolidines - chemical synthesis (140) 140
receptors, opioid - drug effects (140) 140
clinical trials as topic (139) 139
glucagon-like peptide-1 (139) 139
toxicology (139) 139
pyrrolidines - blood (138) 138
apoptosis (134) 134
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4713) 4713
French (69) 69
German (52) 52
Italian (29) 29
Russian (24) 24
Japanese (22) 22
Spanish (12) 12
Chinese (7) 7
Hungarian (4) 4
Polish (3) 3
Portuguese (3) 3
Swedish (3) 3
Danish (2) 2
Bulgarian (1) 1
Czech (1) 1
Dutch (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | METFORMIN-TREATED PATIENTS | HEALTHY-SUBJECTS | 2ND-PHASE INSULIN-SECRETION | IMPROVES GLYCEMIC CONTROL | BETA-CELL APOPTOSIS | IV INHIBITOR | 7-36 AMIDE | IMPROVED GLUCOSE-TOLERANCE | EXENATIDE SYNTHETIC EXENDIN-4 | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents
Journal Article
Journal Article
Addiction Biology, ISSN 1355-6215, 03/2014, Volume 19, Issue 2, pp. 165 - 174
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 67, Issue 2, pp. 263 - 271
Journal Article
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018, Volume 41, Issue 2, pp. 153 - 157
Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide, lixisenatide) have recently been used as anti-diabetes drugs. We examined... 
pharmacokinetics | dipeptidyl peptidase-4 inhibitor | glucagon-like peptide-1 receptor agonist | target molecular binding occupancy | pharmacodynamics | Dipeptidyl peptidase-4 inhibitor | Pharmacodynamics | Pharmacokinetics | Glucagon-like peptide-1 receptor agonist | Target molecular binding occupancy | GLUCAGON-LIKE PEPTIDE-1 | PHARMACOLOGY & PHARMACY | PROMOTES SATIETY | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - metabolism | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Peptides - pharmacokinetics | Nitriles - pharmacokinetics | Peptides - administration & dosage | Peptides - metabolism | Hypoglycemic Agents - administration & dosage | Pyrrolidines - metabolism | Adamantane - therapeutic use | Adamantane - administration & dosage | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Piperidines - administration & dosage | Piperidines - metabolism | Pyrrolidines - pharmacokinetics | Adamantane - metabolism | Models, Molecular | Uracil - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Liraglutide - therapeutic use | Venoms - therapeutic use | Ligands | Venoms - metabolism | Sitagliptin Phosphate - pharmacokinetics | Venoms - pharmacokinetics | Nitriles - therapeutic use | Liraglutide - metabolism | Sitagliptin Phosphate - metabolism | Pyrrolidines - administration & dosage | Diabetes Mellitus, Type 2 - metabolism | Molecular Targeted Therapy | Pyrrolidines - therapeutic use | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Glucagon-Like Peptide-1 Receptor - metabolism | Liraglutide - pharmacokinetics | Uracil - administration & dosage | Venoms - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - metabolism | Piperidines - pharmacokinetics | Adamantane - pharmacokinetics | Nitriles - metabolism | Reproducibility of Results | Diabetes Mellitus, Type 2 - blood | Algorithms | Piperidines - therapeutic use | Sitagliptin Phosphate - therapeutic use | Uracil - metabolism | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Uracil - pharmacokinetics | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - therapeutic use | Uracil - analogs & derivatives | Binding | Drugs | Effectiveness | Peptidase | Glucagon | Diabetes mellitus | Theoretical analysis | Low level | Receptors | Inhibitors | Nitric oxide | Occupancy | Hemoglobin | Agonists | Glucagon-like peptide 1 | Drug dosages
Journal Article
Journal of Pharmacy and Pharmaceutical Sciences, ISSN 1482-1826, 09/2015, Volume 18, Issue 3, pp. 434 - 447
Journal Article
Psychopharmacology, ISSN 0033-3158, 2/2017, Volume 234, Issue 4, pp. 589 - 598
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 651 - 662
Journal Article